Intervacc AB (SE:IVACC)

:IVACC

IVACC

Intervacc AB

RESEARCH TOOLSreports

Intervacc AB (IVACC) Price & Analysis

0 Followers

IVACC Stock Chart & Stats

kr0.92

-kr0.06(-5.24%)

At close: Mar 06 4:00 PM EST

kr0.92

-kr0.06(-5.24%)

Day’s Range― - ―

52-Week Rangekr0.57 - kr1.35

Previous CloseN/A

Volume791.15K

Average Volume (3M)373.34K

Market Cap

kr293.10M

Enterprise Valuekr132.21M

Total Cash (Recent Filing)kr160.89M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.40

Next Earnings

May 13, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding340,813,200

10 Day Avg. Volume453,808

30 Day Avg. Volume373,337

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.00

Price to Sales (P/S)13.68

P/FCF Ratio-4.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.23

Revenue Forecast (FY)kr51.00M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthNear-zero debt materially reduces financial risk and interest costs, giving management runway to fund vaccine development, regulatory submissions, or commercialization without immediate refinancing. This durable capital structure supports long-term product development despite operating losses.

Top-line Growth EpisodesA reported ~70% revenue growth metric shows the company can generate meaningful top-line expansion in some periods, evidencing market demand and commercial traction. Sustained top-line growth, if repeated, underpins scale benefits and provides a pathway to improve margins over time.

Niche Animal-Health FocusSpecialization in bacterial vaccines for livestock creates regulatory, technical, and customer-relationship barriers to entry. This focused model targets recurring vaccination programs and herd-health needs, supporting durable demand, targeted commercial channels, and clearer product-market fit over time.

Bears Say

Gross Loss DeteriorationA large 2025 gross loss despite rising revenue points to adverse product economics or rising COGS that structurally impair margins. Without corrective action (pricing, manufacturing or product mix), gross-loss dynamics threaten the path to profitability and can erode equity and investor support over time.

Persistent Cash BurnConsistent negative operating and free cash flow indicate the business cannot self-fund operations or growth. This durable cash-burn pattern forces reliance on external financing, increases dilution or financing risk, and constrains strategic choices like scaling manufacturing or marketing investments.

Volatile Revenue TrajectoryMarked revenue volatility undermines predictability of demand and complicates planning for production, inventory and sales channels. Inconsistent commercial traction reduces the ability to achieve scale economies, weakens bargaining with distributors, and delays sustainable margin recovery.

IVACC FAQ

What was Intervacc AB’s price range in the past 12 months?

Intervacc AB lowest stock price was kr0.57 and its highest was kr1.35 in the past 12 months.

What is Intervacc AB’s market cap?

Intervacc AB’s market cap is kr293.10M.

When is Intervacc AB’s upcoming earnings report date?

Intervacc AB’s upcoming earnings report date is May 13, 2026 which is in 38 days.

How were Intervacc AB’s earnings last quarter?

Intervacc AB released its earnings results on Feb 17, 2026. The company reported -kr0.1 earnings per share for the quarter, missing the consensus estimate of -kr0.06 by -kr0.04.

Is Intervacc AB overvalued?

According to Wall Street analysts Intervacc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Intervacc AB pay dividends?

Intervacc AB does not currently pay dividends.

What is Intervacc AB’s EPS estimate?

Intervacc AB’s EPS estimate is -0.06.

How many shares outstanding does Intervacc AB have?

Intervacc AB has 340,813,200 shares outstanding.

What happened to Intervacc AB’s price movement after its last earnings report?

Intervacc AB reported an EPS of -kr0.1 in its last earnings report, missing expectations of -kr0.06. Following the earnings report the stock price went down -16.471%.

Which hedge fund is a major shareholder of Intervacc AB?

Currently, no hedge funds are holding shares in SE:IVACC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Intervacc AB

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.